ヒトマイクロバイオーム系薬剤と診断の世界市場

本レポートは、ヒトマイクロバイオームベースの医薬品および診断薬の世界市場と市場動向を分析しています。基準年である2024年の世界市場収益、2025年の予測データ、および2025年から2030年の予測期間における年平均成長率（CAGR）が含まれています。

市場は、タイプ、用途、エンドユーザー、地域別にセグメント化されています。マイクロバイオームベースの医薬品セグメントは、投与経路（経口または直腸）によってさらにセグメント化されています。マイクロバイオームベースの診断薬は、製品タイプに基づいて、機器、試薬、キットに分類されています。エンドユーザーセグメントには、病院、クリニック、製薬会社、研究機関が含まれます。用途には、代謝、胃腸（GI）、感染症、がんなどが含まれます。対象地域は、北米、欧州、アジア太平洋、南米、中東およびアフリカ（MEA）です。本レポートでは、新興技術について解説し、競合状況を分析し、市場をリードする企業のランキング/市場シェアを示しています。また、環境、社会、企業統治（ESG）の発展に関する章も含まれています。

Report Highlights

The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.

ヒトマイクロバイオームベースの医薬品および診断の世界市場は、2025年から2030年にかけて年平均成長率（CAGR）25.6%で成長し、2025年の3億9,340万ドルから2030年末までに12億ドルに達すると予想されています。

Summary:

Human microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestlé Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Biosciences.

Report Scope

The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.

Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.

Report Synopsis

Report Includes

– 55 data tables and 51 additional tables

– Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030

– Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region

– Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables

– Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments

– An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development

– Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes

– An analysis of the key patent grants and recently published patents

– Analysis of the industry structure and value chain, and the competitive landscape, including companies’ market shares, strategic alliances, M&A activity, venture fundings and investment outlook

– Profiles of the leading companies, including Ferring Pharmaceuticals, Nestlé Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Market Dynamics

Emerging Technologies

Analysis by Segment

Regional Analysis

Conclusion

Chapter 2 Market Overview

Overview and Market Definition

Different Microbiomes in Humans

Microbiome, Human Health and Disease

Technologies Aiding Microbiome Research

Culturing and Cultivation

Strategies for the Development of Microbiome Therapeutics

Additive Microbiome Therapy

Modulatory Microbiome Therapy

Analysis of Macroeconomic Factors

Geopolitical Factors

Inflation and Currency Exchange Fluctuations

Porter’s Five Forces Analysis

Chapter 3 Market Dynamics

Takeaways

Market Drivers

Growing Evidence of Microbiome-disease Correlation

Microbiome-based Diagnostics for Disease Prevention and Monitoring

Market Restraints

Challenges in Clinical Trial Design

Lack of Established Regulatory Frameworks

High Costs of Microbiome Therapeutics

Market Opportunities

Direct-to-Consumer Microbiome Testing

Drugs and Diagnostics for Lung and Skin Microbiomes

Chapter 4 Regulatory Landscape

Regulatory Aspects

North America

Europe

Asia-Pacific

Chapter 5 Emerging Technologies

Takeaways

Emerging Technologies

Microbial Ecosystem Therapeutics

Metatranscriptome Sequencing

Genetically Modified Microbiome Therapeutics

Combination and Adjuvant Therapies with Microbiome-based Drugs

Novel Preclinical Models

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown

Market Analysis by Type

Microbiome-based Drugs

Market Analysis by Application

Infectious Diseases

GI Disorders

Metabolic Disorders

Cancer

Other Diseases

Market Analysis by End User

Hospitals and Clinics

Research Institutions

Pharmaceutical Companies

Geographic Breakdown

Market Analysis by Region

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Chapter 7 Competitive Intelligence

Takeaways

Company Share Analysis

Competitive Analysis

Venture Funding and Investment Landscape

Recent Developments

Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective

Introduction to ESG

ESG Risk Ratings

Concluding Remarks

Chapter 9 Appendix

Methodology

Sources

Abbreviations

Company Profiles

BIOMEBANK

ENTEROBIOTIX LTD.

ENTEROME

FERRING

GENETIC ANALYSIS

ILLUMINA INC.

MICROBIOME INSIGHTS

MICROBIOTICA

NESTLE HEALTH SCIENCE

OXFORD NANOPORE TECHNOLOGIES PLC

PACBIO

SFA THERAPEUTICS INC.

THERMO FISHER SCIENTIFIC INC.

VEDANTA BIOSCIENCES INC.

Emerging Start-ups/Market Disruptors

List of Tables

Summary Table : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030

Table 1 : Technology for Microbiome Research

Table 2 : Diseases Associated with Microbiome Dysbiosis

Table 3 : Microbiome-based Drug Nomenclature

Table 4 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030

Table 5 : Global Market for Human Microbiome-based Drugs, by Route of Administration, Through 2030

Table 6 : Global Market for Human Microbiome-based Drugs, by Region, Through 2030

Table 7 : Global Market for Human Microbiome-based Drugs, by Rectal Route of Administration, by Region, Through 2030

Table 8 : Global Market for Human Microbiome-based Drugs, by Oral Route of Administration, by Region, Through 2030

Table 9 : Global Market for Human Microbiome-based Diagnostics, by Region, Through 2030

Table 10 : Global Market for Human Microbiome-based Diagnostics, by Product Type, Through 2030

Table 11 : Global Market for Human Microbiome-based Diagnostics Reagents and Kits, by Region, Through 2030

Table 12 : Global Market for Human Microbiome-based Diagnostic Instruments, by Region, Through 2030

Table 13 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Application, Through 2030

Table 14 : Global Market for Human Microbiome-based Drugs and Diagnostics for Infectious Diseases, by Region, Through 2030

Table 15 : Global Market for Human Microbiome-based Drugs and Diagnostics for GI Disorders, by Region, Through 2030

Table 16 : Global Market for Human Microbiome-based Drugs and Diagnostics for Metabolic Disorders, by Region, Through 2030

Table 17 : Global Market for Human Microbiome-based Drugs and Diagnostics for Cancer, by Region, Through 2030

Table 18 : Microbiome-based Drugs in the Pipeline for Cancer Therapy

Table 19 : Global Market for Human Microbiome-based Drugs and Diagnostics for Other Diseases, by Region, Through 2030

Table 20 : Global Market for Human Microbiome-based Drugs and Diagnostics, by End User, Through 2030

Table 21 : Global Market for Microbiome-based Drugs and Diagnostics for Hospitals and Clinics, by Region, Through 2030

Table 22 : Global Market for Microbiome-based Drugs and Diagnostics for Research Institutions, by Region, Through 2030

Table 23 : Global Market for Microbiome-based Drugs and Diagnostics for Pharmaceutical Firms, by Region, Through 2030

Table 24 : Global Market for Human Microbiome-based Drugs and Diagnostics, by Region, Through 2030

Table 25 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030

Table 26 : North American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030

Table 27 : North American Market for Microbiome-based Drugs, by Route of Administration, Through 2030

Table 28 : North American Market for Microbiome-based Diagnostics, by Product Type, Through 2030

Table 29 : North American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030

Table 30 : North American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030

Table 31 : European Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030

Table 32 : European Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030

Table 33 : European Market for Microbiome-based Drugs, by Route of Administration, Through 2030

Table 34 : European Market for Microbiome-based Diagnostics, by Product Type, Through 2030

Table 35 : European Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030

Table 36 : European Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030

Table 37 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Country, Through 2030

Table 38 : Asia-Pacific Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030

Table 39 : Asia-Pacific Market for Microbiome-based Drugs, by Route of Administration, Through 2030

Table 40 : Asia-Pacific Market for Microbiome-based Diagnostics, by Product Type, Through 2030

Table 41 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030

Table 42 : Asia-Pacific Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030

Table 43 : South American Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030

Table 44 : South American Market for Microbiome-based Drugs, by Route of Administration, Through 2030

Table 45 : South American Market for Microbiome-based Diagnostics, by Product Type, Through 2030

Table 46 : South American Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030

Table 47 : South American Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030

Table 48 : MEA Market for Human Microbiome-based Drugs and Diagnostics, by Type, Through 2030

Table 49 : MEA Market for Microbiome-based Drugs, by Administration Route, Through 2030

Table 50 : MEA Market for Microbiome-based Diagnostics, by Product Type, Through 2030

Table 51 : MEA Market for Microbiome-based Drugs and Diagnostics, by Application, Through 2030

Table 52 : MEA Market for Microbiome-based Drugs and Diagnostics, by End User, Through 2030

Table 53 : Competitive Analysis of Human Microbiome-based Diagnostics Market

Table 54 : Venture Funding in the Human Microbiome-based Drugs and Diagnostics Market, 2024

Table 55 : Recent Developments in the Human Microbiome-based Drug and Diagnostics Market, 2022–2025

Table 56 : ESG Goals of Human Microbiome-based Drugs and Diagnostics Companies

Table 57 : ESG Risk Ratings for Human Microbiome-based Drugs and Diagnostics Firms, 2025

Table 58 : Report Information Sources

Table 59 : Abbreviations Used in this Report

Table 60 : BiomeBank: Company Snapshot

Table 61 : BiomeBank: Product Portfolio

Table 62 : BiomeBank: News/Key Developments, 2024

Table 63 : EnteroBiotix Ltd.: Company Snapshot

Table 64 : EnteroBiotix Ltd.: Product Portfolio

Table 65 : EnteroBiotix Ltd.: News/Key Developments, 2024

Table 66 : Enterome: Company Snapshot

Table 67 : Enterome: Product Portfolio

Table 68 : Enterome: News/Key Developments, 2022

Table 69 : Ferring: Company Snapshot

Table 70 : Ferring: Financial Performance, FY 2022 and 2023

Table 71 : Ferring: Product Portfolio

Table 72 : Ferring: News/Key Developments, 2022 and 2023

Table 73 : Genetic Analysis: Company Snapshot

Table 74 : Genetic Analysis: Financial Performance, FY 2023 and 2024

Table 75 : Genetic Analysis: Product Portfolio

Table 76 : Genetic Analysis: News/Key Developments, 2024

Table 77 : Illumina Inc.: Company Snapshot

Table 78 : Illumina Inc.: Financial Performance, FY 2023 and 2024

Table 79 : Illumina Inc.: Product Portfolio

Table 80 : Microbiome Insights: Company Snapshot

Table 81 : Microbiome Insights: Product Portfolio

Table 82 : Microbiome Insights: News/Key Developments, 2024

Table 83 : Microbiotica: Company Snapshot

Table 84 : Microbiotica: Product Portfolio

Table 85 : Microbiotica: News/Key Developments, 2023

Table 86 : Nestle Health Science: Company Snapshot

Table 87 : Nestle Health Science: Product Portfolio

Table 88 : Nestle Health Science: News/Key Developments, 2024

Table 89 : Oxford Nanopore Technologies plc: Company Snapshot

Table 90 : Oxford Nanopore Technologies plc: Financial Performance, FY 2023 and 2024

Table 91 : Oxford Nanopore Technologies plc.: Product Portfolio

Table 92 : PacBio: Company Snapshot

Table 93 : PacBio: Financial Performance, FY 2023 and 2024

Table 94 : PacBio: Product Portfolio

Table 95 : PacBio: News/Key Developments, 2025

Table 96 : SFA Therapeutics Inc.: Company Snapshot

Table 97 : SFA Therapeutics Inc.: Product Portfolio

Table 98 : SFA Therapeutics Inc.: News/Key Developments, 2024

Table 99 : Thermo Fisher Scientific Inc.: Company Snapshot

Table 100 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024

Table 101 : Thermo Fisher Scientific Inc.: Product Portfolio

Table 102 : Vedanta Biosciences Inc.: Company Snapshot

Table 103 : Vedanta Biosciences Inc.: Product Portfolio

Table 104 : Vedanta Biosciences Inc.: News/Key Developments, 2023

Table 105 : Emerging Startups

List of Figures

Summary Figure : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024

Figure 1 : Essential Functions of the Human Microbiome

Figure 2 : Porter’s Five Forces Analysis of the Human Microbiome-based Drugs and Diagnostics Market

Figure 3 : Human Microbiome-based Drugs and Diagnostics Market Dynamics

Figure 4 : Diseases and Conditions Associated with Dysbiosis

Figure 5 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Type, 2024

Figure 6 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Application, 2024

Figure 7 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by End User, 2024

Figure 8 : Global Market Shares of Human Microbiome-based Drugs and Diagnostics, by Region, 2024

Figure 9 : North American Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024

Figure 10 : European Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024

Figure 11 : Asia-Pacific Market Shares of Human Microbiome-based Drugs and Diagnostics, by Country, 2024

Figure 12 : Company Shares in the Human Microbiome-based Drug Market, 2024

Figure 13 : Ferring: Revenue Share, by Business Unit, FY 2023

Figure 14 : Ferring: Revenue Share, by Country/Region, FY 2023

Figure 15 : Genetic Analysis: Revenue Share, by Business Unit, FY 2024

Figure 16 : Genetic Analysis: Revenue Share, by Country/Region, FY 2024

Figure 17 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024

Figure 18 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024

Figure 19 : Oxford Nanopore Technologies plc: Revenue Share, by Business Unit, FY 2024

Figure 20 : Oxford Nanopore Technologies plc: Revenue Share, by Country/Region, FY 2024

Figure 21 : PacBio: Revenue Share, by Business Unit, FY 2024

Figure 22 : PacBio: Revenue Share, by Country/Region, FY 2024

Figure 23 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2024

Figure 24 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2024

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自律型無人潜水機の2030年までの世界市場 2025-06-06
• 世界のSDV(ソフトウェア・デファインド・ビークル)市場 2025-06-06
• 高分子発泡体の世界市場 2025-06-06
• 世界の細胞株と細胞膜市場 2025-06-05
• 世界のエッジAI市場 2025-06-03

BCC Research  出版レポート一覧